Compounds > tomopenem
Page last updated: 2024-11-11

tomopenem

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9809656
CHEMBL ID389847
SCHEMBL ID304829
MeSH IDM0535761

Synonyms (43)

Synonym
r-1558
tomopenem
ro-4908463
r-115685
cs-023
(4r,5s,6s)-3-[(3s,5s)-5-[(3s)-3-[(2-guanidinoacetyl)amino]pyrrolidine-1-carbonyl]-1-methyl-pyrrolidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4r,5s,6s)-3-{[(3s,5s)-5-{[(3s)-3-{[n-(diaminomethylidene)glycyl]amino}pyrrolidin-1-yl]carbonyl}-1-methylpyrrolidin-3-yl]sulfanyl}-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
r-1l5685
CHEMBL389847
ro4908463
D09022
222400-20-6
tomopenem (usan/inn)
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3s,5s)-5-(((3s)-3-((((aminoiminomethyl)amino)acetyl)amino)-1-pyrrolidinyl)carbonyl)-1-methyl-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, (4r,5s,6s)-
(4r,5s,6s)-3-(((3s,5s)-5-(((3s)-3-((2-guanidinoacetyl)amino)pyrrolidin-1-yl)carbonyl)-1-methylpyrrolidin-3-yl)sulfanyl)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
ro 4908463
cs 023
(4r,5s,6s)-3-(((3s,5s)-5-((3s)-3-(carbamimidamidoacetamido)pyrrolidine-1-carbonyl)-1-methylpyrrolidin-3-yl)sulfanyl)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
tomopenem [usan:inn]
r 1558
antibiotic cs 023
unii-1654w9611t
cs023 cpd
1654w9611t ,
r 115685
r115685
tomopenem [inn]
tomopenem [usan]
tomopenem [who-dd]
SCHEMBL304829
(4r,5s,6s)-3-(((3s,5s)-5-((s)-3-(2-guanidinoacetamido)pyrrolidine-1-carbonyl)-1-methylpyrrolidin-3-yl)thio)-6-((r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
AKOS027250771
KEDAXBWZURNCHS-GPODMPQUSA-N
(1r,5s,6s)-2-[(2s,4s)-2-[(3s)-3-(2-guanidinoacetylamino)pyrrolidin-1-ylcarbonyl]-1-methylpyrrolidin-4-ylthio]-6-[(1r)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid
(1r,5s,6s)-6-[(1r)-1-hydroxyethyl]-1-methyl-2-[(2s,4s)-2-[(3s)-3-(2-guanidinoacetylamino)pyrrolidin-1-ylcarbonyl]-1-methylpyrrolidin-4-ylthio]-1-carbapen-2-em-3-carboxylic acid
bdbm50483019
DTXSID70873384
Q15427876
(4r,5s,6s)-3-[(3s,5s)-5-[(3s)-3-[[2-(diaminomethylideneamino)acetyl]amino]pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
cs023
gtpl10869
CS-0079886
HY-123022

Research Excerpts

Overview

Tomopenem (CS-023) is a novel parenteral carbapenem with broad-spectrum activity against Gram-positive and -negative bacteria. It has potent activity against drug-resistant pathogens, including penicillin-resistant Streptococcus pneumoniae and Pseudomonas aeruginosa.

ExcerptReferenceRelevance
"Tomopenem (CS-023) is a novel parenteral carbapenem with broad-spectrum activity against Gram-positive and -negative bacteria, as well as potent activity against drug-resistant pathogens, including penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. "( In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamada, Y; Yamamoto, K; Yamamoto, Y; Yanagihara, K, 2008)		2.05

Pharmacokinetics

tomopenem treatment of chronic airway infection with P. We examined the in vivo pharmacodynamic characteristics of tom Openem against P.

ExcerptReferenceRelevance
"06 mg/liter) were studied in an in vitro pharmacokinetic model."( Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
Bowker, KE; MacGowan, AP; Noel, AR, 2008)		0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008)		0.35
" The pharmacokinetic parameter of % time above MIC for tomopenem and meropenem was 16% and 17% in sera and 15% and 18% in lungs, respectively."( In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamada, Y; Yamamoto, K; Yamamoto, Y; Yanagihara, K, 2008)		0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (570)

Assay IDTitleYearJournalArticle
AID534672Antimicrobial activity against Porphyromonas asaccharolyticus ATCC 25260 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545335Displacement of [14C]benzylpenicillin from PBP2 Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520038Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 in in vitro pharmacokinetic model assessed as viable count at 2 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529023Ratio of RO4957463 AUC (infinity) to compound AUC (infinity) in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID528884Tmax in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520540AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519946Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 by 10% MH broth method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534688Antimicrobial activity against Bacteroides caccae by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534476Antimicrobial activity against Sutterella wadsworthensis ATCC 51579 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520941Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545351Displacement of [14C]benzylpenicillin from PBP 6 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545555Antibacterial activity against Escherichia coli ERR8a selected at 8 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520424Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520425Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534709Antimicrobial activity against Clostridium difficile by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545569Antibacterial activity against Pseudomonas aeruginosa PRR4a selected at 4 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520929Antibacterial activity against methicillin-sensitive Staphylococcus aureus2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529864Ratio of MIC for Pseudomonas aeruginosa COR6 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID534462Antimicrobial activity against Bacteroides fragilis NCTC 10581 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520037T>MIC in methicillin-resistant Staphylococcus aureus 33815 infected in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534683Antimicrobial activity against Bacteroides fragilis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520050Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 in in vitro pharmacokinetic model assessed as viable count at 6 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520694T>MIC for 4-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534441Antimicrobial activity against Clostridium septicum ATCC 12464 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520678T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534703Antimicrobial activity against Finegoldia magna by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534691Antimicrobial activity against Prevotella intermedia by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520054Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model assessed as viable count at 6 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528901Total clearance in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534687Antimicrobial activity against Bacteroides vulgatus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520655T>MIC for static effect in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545559Antibacterial activity against Escherichia coli EIR2b selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520079Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID534669Antimicrobial activity against Prevotella denticola GAI 5490 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520165Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520662T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520650Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 assessed as viable count at 4 times of MIC after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545332Antibacterial activity against Escherichia coli NIHJ by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID278637AUC (0-inf) in rat at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534469Antimicrobial activity against Parabacteroides distasonis ATCC 8503 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528906Drug metabolism in human with creatinine clearance of 30-49 ml/min assessed as RO4957463 Cmax at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534479Antimicrobial activity against Prevotella corporis GAI 91000 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520065Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519941Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 by broth dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534690Antimicrobial activity against Odoribacter splanchnicus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520052Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model assessed as viable count at 6 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520649Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 assessed as viable count at 4 times of MIC after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519948Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 by 10% MH broth method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520948Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520158Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519947Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 by 10% MH broth method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528910Drug metabolism in human with creatinine clearance of 30-49 ml/min assessed as RO4957463 Tmax at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545331Antibacterial activity against Staphylococcus aureus ATCC 6538P by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID534431Antimicrobial activity against Peptoniphilus asaccharolyticus WAL 3218 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520672T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534689Antimicrobial activity against Bacteroides stercoris by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529852Antibacterial activity against beta-lactamase-overproducing and OprD-deficient Pseudomonas aeruginosa N044 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520146Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520136Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529030Drug excretion in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534708Antimicrobial activity against Eubacterium limosum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520523Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534453Antimicrobial activity against Lactobacillus acidophilus JCM 1132 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529851Antibacterial activity against MexA-MexB-OprM-overproducing Pseudomonas aeruginosa OCR1 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID534458Antimicrobial activity against Lactobacillus reuteri JCM 1112 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID278655Volume of distribution at steady state in rat at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID278635Half life in monkey at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534676Antimicrobial activity against Fusobacterium necrophorum ATCC 25286 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545547Antibacterial activity against Staphylococcus aureus SMR4a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520659T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519945Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 by 10% MH broth method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520679T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534710Antimicrobial activity against Clostridium perfringens by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520656T>MIC for static effect in methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534693Antimicrobial activity against Prevotella melaninogenica by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528898Volume of distribution at steady state in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520658T>MIC for 1-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545575Antibacterial activity against Staphylococcus aureus ATCC 6538P assessed as fold decrease in compound susceptibility after 10 passages relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID534450Antimicrobial activity against Eggerthella lenta ATCC 25559 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534686Antimicrobial activity against Bacteroides uniformis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520152Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520947Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520544AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519954T>MIC in methicillin-resistant Staphylococcus aureus 33922 infected in vitro pharmacokinetic model at 750 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278628Half life in rat at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID545344Displacement of [14C]benzylpenicillin from PBP6 Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID529855Antibacterial activity against Pseudomonas aeruginosa COR6 expressing MexC-MexD-OprJ gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID534452Antimicrobial activity against Propionibacterium granulosum ATCC 25564 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529022Ratio of RO4957463 AUC (infinity) to compound AUC (infinity) in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520667T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520676T>MIC for 4-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529847Binding affinity to PBP2a in methicillin-resistant Staphylococcus aureus 12386-1 by [14C]benzylpenicillin labelled competitive assay2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID534697Antimicrobial activity against Fusobacterium nucleatum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID278625Protein binding in dog serum at 100 ug/ml2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534698Antimicrobial activity against Fusobacterium necrophorum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534429Antimicrobial activity against Finegoldia magna ATCC 29328 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520078Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529051Total clearance in healthy human at 700 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520651Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 assessed as viable count at 4 times of MIC after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520143Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545346Displacement of [14C]benzylpenicillin from PBP1B in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545578Antibacterial activity against methicillin-resistant Staphylococcus aureus by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID529859Ratio of MIC for Pseudomonas aeruginosa MR08 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID278660Volume of distribution at steady state in dog at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520043Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model assessed as viable count at 2 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520654T>MIC for static effect in methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520045Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model assessed as viable count at 4 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545566Ratio of MIC for Escherichia coli EIR8a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID529052Volume of distribution in healthy human at 700 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID529020Drug metabolism in human with creatinine clearance of 30-49 ml/min assessed as RO4957463 AUC (infinity) at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520660T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534435Antimicrobial activity against Staphylococcus saccharolyticus ATCC 14953 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534478Antimicrobial activity against Prevotella buccae ATCC 33574 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534448Antimicrobial activity against Bifidobacterium longum subsp. longum ATCC 15707 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520539AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278639AUC (0-inf) in rat at 50 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID519949Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 by 10% MH broth method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520033T>MIC in methicillin-resistant Staphylococcus aureus 33829 infected in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545343Displacement of [14C]benzylpenicillin from PBP5 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520437AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529841Antibacterial activity against Pseudomonas aeruginosa clinical isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID545345Displacement of [14C]benzylpenicillin from PBP1A in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520073Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520450AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529027Renal clearance in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID529863Ratio of MIC for Pseudomonas aeruginosa N041 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520061Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534704Antimicrobial activity against Parvimonas micra by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528882Cmax in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534475Antimicrobial activity against Campylobacter gracilis JCM 8538 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID278626Protein binding in monkey serum at 20 ug/ml2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID528907Drug metabolism in human with creatinine clearance of =< 30 ml/min assessed as RO4957463 Cmax at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520153Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID534692Antimicrobial activity against Prevotella sp. by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID519958T>MIC in methicillin-resistant Staphylococcus aureus 33921 infected in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID278640AUC (0-inf) in dog at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID278662Volume of distribution at steady state in monkey at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520541AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520465Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545576Antibacterial activity against Pseudomonas aeruginosa ATCC 15692 assessed as fold decrease in compound susceptibility after 10 passages relative to control2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520683T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534701Antimicrobial activity against Fusobacterium sp. by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520076Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520426AUBKC (0 to 24 hrs) in methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534668Antimicrobial activity against Prevotella melaninogenica JCM 6325 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534706Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520471Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278623Protein binding in rat serum at 100 ug/ml2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534696Antimicrobial activity against Porphyromonas uenonis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520545AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520049Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model assessed as viable count at 4 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520680T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545334Displacement of [14C]benzylpenicillin from PBP1 in Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID278629Half life in rat at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534467Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30144 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID519944Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 by broth dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520930Antibacterial activity against methicillin-resistant Staphylococcus aureus2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519942Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 by broth dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528890Apparent half-life in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID529856Antibacterial activity against Pseudomonas aeruginosa N091 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID534677Antimicrobial activity against Bilophila wadsworthia WAL 7959 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528911Drug metabolism in human with creatinine clearance of =< 30 ml/min assessed as RO4957463 Tmax at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534456Antimicrobial activity against Lactobacillus fermentum JCM 1173 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534480Antimicrobial activity against Prevotella heparinolytica ATCC 35895 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520428AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534449Antimicrobial activity against Bifidobacterium pseudolongum ATCC 25526 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529034Dose normalized excretion in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID519953T>MIC in methicillin-resistant Staphylococcus aureus 33921 infected in vitro pharmacokinetic model at 750 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278654Clearance in monkey at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520932Drug level in human serum at 1400 mg2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520060Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534428Antimicrobial activity against Atopobium parvulum VPI 0546 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520162Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529017Drug metabolism in human with creatinine clearance of =< 30 ml/min assessed as RO4957463 apparent half life at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534684Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534439Antimicrobial activity against Clostridium difficile GAI 10029 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520567Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 assessed as viable count at 2 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519940Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 by broth dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529036Dose normalized excretion in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520685T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278661Volume of distribution at steady state in monkey at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520141Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545350Displacement of [14C]benzylpenicillin from PBP 5 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545338Displacement of [14C]benzylpenicillin from PBP1A in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID529021Drug metabolism in human with creatinine clearance of =< 30 ml/min assessed as RO4957463 AUC (infinity) at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545358Antibacterial activity against Staphylococcus aureus SIR2a selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545357Ratio of MIC for Staphylococcus aureus SRR2a to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520034T>MIC in methicillin-resistant Staphylococcus aureus 33820 infected in vitro pharmacokinetic model at 750 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520157Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520169Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545333Antibacterial activity against Pseudomonas aeruginosa ATCC 15692 by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545552Ratio of MIC for Escherichia coli ERR2b to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520140Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545336Displacement of [14C]benzylpenicillin from PBP3 in Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID278652Clearance in monkey at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520431AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520170Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520172Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528908Drug metabolism in human with creatinine clearance of => 80 ml/min assessed as RO4957463 Tmax at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520155Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545564Ratio of MIC for Escherichia coli EIR4b to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID534671Antimicrobial activity against Prevotella oris ATCC 33573 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545337Displacement of [14C]benzylpenicillin from PBP4 in Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520059Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520151Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520568Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 assessed as viable count at 2 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545554Ratio of MIC for Escherichia coli ERR4a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545574Ratio of MIC for Pseudomonas aeruginosa PMR2a to MIC for Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520464Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520068Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520430AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520468Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529840Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID278656Volume of distribution at steady state in rat at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520534AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534454Antimicrobial activity against Lactobacillus brevis subsp. brevis JCM 1059 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520940Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520062Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520661T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520928T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520074Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529857Antibacterial activity against Pseudomonas aeruginosa N092 expressing MexE-MexD-OprN gene and OprD mutant gene and harboring nfxC mutant gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520135Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520067Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520533Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520442AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534437Antimicrobial activity against Streptococcus intermedius ATCC 27335 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520435AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520070Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520463Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528885Tmax in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID528909Drug metabolism in human with creatinine clearance of 50-79 ml/min assessed as RO4957463 Tmax at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520171Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534463Antimicrobial activity against Bacteroides fragilis GAI 0558 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534447Antimicrobial activity against Bifidobacterium breve ATCC 15700 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520648Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 assessed as viable count at 4 times of MIC after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278620Drug excretion in rat urine assessed as radioactivity at 10 mg/kg, iv after 24 h2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID529850Antibacterial activity against OprD-deficient Pseudomonas aeruginosa MR08 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520457Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520053Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model assessed as viable count at 6 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520440AUBKC (0 to 48 hrs) in methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529862Ratio of MIC for Pseudomonas aeruginosa N045 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520072Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520524Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520645Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 assessed as viable count at 4 times of MIC after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520057Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545577Antibacterial activity against methicillin-sensitive Staphylococcus aureus by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID278634Half life in monkey at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID545339Displacement of [14C]benzylpenicillin from PBP1B in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520032T>MIC in methicillin-resistant Staphylococcus aureus 33827 infected in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528893AUC (infinity) in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520056Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529860Ratio of MIC for Pseudomonas aeruginosa OCR1 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520461Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519943Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 by broth dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520166Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520147Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520933Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534700Antimicrobial activity against Fusobacterium mortiferum by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534674Antimicrobial activity against Fusobacterium nucleatum ATCC 25586 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534670Antimicrobial activity against Prevotella oralis ATCC 33269 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534699Antimicrobial activity against Fusobacterium varium by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528905Drug metabolism in human with creatinine clearance of 50-79 ml/min assessed as RO4957463 Cmax at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID278617Fecal excretion in rat assessed as radioactivity at 10 mg/kg, iv after 24 h2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534455Antimicrobial activity against Lactobacillus casei subsp. casei JCM 1134 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529026Renal clearance in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520154Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519951Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 by 10% MH broth method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520682T>MIC for 1-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534682Antimicrobial activity against Veillonella dispar ATCC 17748 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520459Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519950Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 by 10% MH broth method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520951Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534673Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520952Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278651Clearance in dog at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520167Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520646Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 assessed as viable count at 4 times of MIC after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278630Half life in rat at 50 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520444AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278641AUC (0-inf) in dog at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID545548Ratio of MIC for Staphylococcus aureus SMR4a to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID528895AUC (infinity) in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520080Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520039Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model assessed as viable count at 2 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534707Antimicrobial activity against Eggerthella lenta by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545557Antibacterial activity against Escherichia coli EIR2a selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID528894AUC (infinity) in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534451Antimicrobial activity against Propionibacterium acnes ATCC 11828 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534695Antimicrobial activity against Porphyromonas gingivalis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534443Antimicrobial activity against Clostridium ramosum ATCC 25582 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534473Antimicrobial activity against Bacteroides eggerthii ATCC 27754 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520458Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534702Antimicrobial activity against Desulfovibrio desulfuricans by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID519952T>MIC in methicillin-sensitive Staphylococcus aureus 5956 infected in vitro pharmacokinetic model at 750 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534433Antimicrobial activity against Peptostreptococcus anaerobius ATCC 27337 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528892AUC (infinity) in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520432AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520640Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 assessed as viable count at 2 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529025Ratio of RO4957463 AUC (infinity) to compound AUC (infinity)) in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520443AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520163Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534460Antimicrobial activity against Bacteroides fragilis GAI 5562 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545545Antibacterial activity against Staphylococcus aureus SMR2a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID534705Antimicrobial activity against Peptostreptococcus anaerobius by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520949Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519959T>MIC in methicillin-resistant Staphylococcus aureus 33922 infected in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520139Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520569Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 assessed as viable count at 2 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528912Drug metabolism in human with creatinine clearance of => 80 ml/min assessed as RO4957463 apparent half life at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520176Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278616Urinary excretion in rat assessed as radioactivity at 10 mg/kg, iv after 24 h2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520046Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model assessed as viable count at 4 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520522Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528897Volume of distribution at steady state in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534667Antimicrobial activity against Prevotella intermedia ATCC 25611 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534459Antimicrobial activity against Lactobacillus salivarius subsp. salivarius JCM 1231 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520688T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278658Volume of distribution at steady state in dog at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID528902Total clearance in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545556Ratio of MIC for Escherichia coli ERR8a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520934Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520066Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520652T>MIC for static effect in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520454Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529018Drug metabolism in human with creatinine clearance of => 80 ml/min assessed as RO4957463 AUC (infinity) at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID519957T>MIC in methicillin-sensitive Staphylococcus aureus 5956 infected in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520693T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520441AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528888Apparent half-life in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID278636Half life in monkey at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID278643AUC (0-inf) in monkey at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534440Antimicrobial activity against Clostridium perfringens ATCC 13124 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID278663Volume of distribution at steady state in monkey at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID278653Clearance in monkey at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520455Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534432Antimicrobial activity against Peptoniphilus indolicus GAI 0915 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529019Drug metabolism in human with creatinine clearance of 50-79 ml/min assessed as RO4957463 AUC (infinity) at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520944Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520647Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 assessed as viable count at 4 times of MIC after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520445AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520543AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520946Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520164Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520168Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520040Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model assessed as viable count at 2 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545567Antibacterial activity against Escherichia coli EMR2a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID519937Plasma protein binding in human2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520042Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model assessed as viable count at 2 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534470Antimicrobial activity against Bacteroides ovatus ATCC 8483 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID529854Antibacterial activity against MexA-MexB-OprM-overproducing and OprD-deficient Pseudomonas aeruginosa N041 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID278650Clearance in dog at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520643Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 assessed as viable count at 4 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545340Displacement of [14C]benzylpenicillin from PBP2 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID528900Total clearance in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520937Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545572Ratio of MIC for Pseudomonas aeruginosa PIR2a to MIC for Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520526Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520055Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model assessed as viable count at 6 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520687T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545354Antibacterial activity against Pseudomonas aeruginosa ATCC 15692 assessed as filamentation of cells at 0.125 times MIC by scanning electron microscopy2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520156Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534436Antimicrobial activity against Streptococcus constellatus ATCC 27923 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520657T>MIC for static effect in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520063Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520935Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520531Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545561Antibacterial activity against Escherichia coli EIR4a selected at 4 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520666T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520449AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520538AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534427Antimicrobial activity against Anaerococcus prevotii ATCC 9321 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528880Cmax in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID519955T>MIC in methicillin-resistant Staphylococcus aureus 33827 infected in vitro pharmacokinetic model at 750 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520047Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model assessed as viable count at 4 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534472Antimicrobial activity against Bacteroides uniformis ATCC 8492 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534680Antimicrobial activity against Capnocytophaga ochracea GAI 5586 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520530Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528883Cmax in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID528881Cmax in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545352Antibacterial activity against Escherichia coli NIHJ assessed as appearance of swollen cells at 1/8 times MIC by Scanning electron microscopy2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520071Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529029Renal clearance in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520439AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529032Drug excretion in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520145Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID529865Ratio of MIC for Pseudomonas aeruginosa N092 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID278621Drug excretion in rat fecus at 10 mg/kg, iv after 24 h2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID278622Protein binding in rat serum at 20 ug/ml2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534675Antimicrobial activity against Fusobacterium varium ATCC 8501 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545549Antibacterial activity against Escherichia coli ERR2a selected at 2 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520537AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520542AUBKC (0 to 48 hrs) in against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534464Antimicrobial activity against Bacteroides fragilis GAI 7955 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520148Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520462Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520668T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520150Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529861Ratio of MIC for Pseudomonas aeruginosa N044 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520570Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 assessed as viable count at 2 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545571Antibacterial activity against Pseudomonas aeruginosa PIR2a selected at 2 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520689T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520064Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534438Antimicrobial activity against Clostridium clostridioforme NCTC 11224 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528891Apparent half-life in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID278659Volume of distribution at steady state in dog at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520036T>MIC in methicillin-resistant Staphylococcus aureus 33820 infected in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520669T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520663T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520429AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520642Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 assessed as viable count at 2 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529031Drug excretion in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520144Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534442Antimicrobial activity against Clostridium sordellii ATCC 9714 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520943Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278631Half life in dog at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID278657Volume of distribution at steady state in rat at 50 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520438AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520690T>MIC for 3-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534694Antimicrobial activity against Porphyromonas asaccharolyticus by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520467Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520044Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 in in vitro pharmacokinetic model assessed as viable count at 4 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520684T>MIC for 1-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520670T>MIC for 3-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545349Displacement of [14C]benzylpenicillin from PBP4 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545356Antibacterial activity against Staphylococcus aureus SRR2a selected at 2 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520433AUBKC (0 to 24 hrs) in methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529844Antibacterial activity against methicillin-resistant Staphylococcus aureus 123-1 expressing PBP 2a by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID278649Clearance in dog at 5 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520525Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520536AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278633Half life in dog at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520069Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520175Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545355Antibacterial activity against Pseudomonas aeruginosa ATCC 15692 assessed as appearance of bulge cells at MIC by Scanning electron microscopy2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520644Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 assessed as viable count at 4 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520134Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278646Clearance in rat at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID545551Antibacterial activity against Escherichia coli ERR2b selected at 2 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545562Ratio of MIC for Escherichia coli EIR4a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID278624Protein binding in dog serum at 20 ug/ml2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID278642AUC (0-inf) in dog at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID545563Antibacterial activity against Escherichia coli EIR4b selected at 4 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520456Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520446AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520035T>MIC in methicillin-resistant Staphylococcus aureus 33815 infected in vitro pharmacokinetic model at 750 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529853Antibacterial activity against beta-lactamase and MexA-MexB-OprM-overproducing Pseudomonas aeruginosa N045 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID529050Half life in healthy human at 700 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520447AUBKC (0 to 48 hrs) in methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529035Dose normalized excretion in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID534685Antimicrobial activity against Parabacteroides distasonis by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545347Displacement of [14C]benzylpenicillin from PBP2 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID528887Tmax in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID528914Drug metabolism in human with creatinine clearance of 30-49 ml/min assessed as RO4957463 apparent half life at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520058Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520945Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520173Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529849Antibacterial activity against beta-lactamase-overproducing Pseudomonas aeruginosa N043 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520664T>MIC for 2-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278647Clearance in rat at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID519956T>MIC in methicillin-resistant Staphylococcus aureus 33829 infected in vitro pharmacokinetic model at 750 mg, iv every 8 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528903Total clearance in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose after 60 mins after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545570Ratio of MIC for Pseudomonas aeruginosa PRR4a to MIC for Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545353Antibacterial activity against Escherichia coli NIHJ assessed as appearance of spherical and bulge cells at 8 times MIC by Scanning electron microscopy2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID529845Antibacterial activity against methicillin-resistant Staphylococcus aureus 12386-1 expressing PBP 2a by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520535AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520075Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534474Antimicrobial activity against Bacteroides ureolyticus NCTC 10941 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520938Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520160Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520451AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520673T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520137Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278632Half life in dog at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID529024Ratio of RO4957463 AUC (infinity) to compound AUC (infinity) in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545565Antibacterial activity against Escherichia coli EIR8a selected at 8 times MIC of imipenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520470Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528886Tmax in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520448AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520174Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520927T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520674T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529846Binding affinity to PBP2a in methicillin-resistant Staphylococcus aureus 123-1 by [14C]benzylpenicillin labelled competitive assay2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520671T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520665T>MIC for 2-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520434AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278638AUC (0-inf) in rat at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520051Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model assessed as viable count at 6 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534465Antimicrobial activity against Bacteroides fragilis GAI 10150 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534446Antimicrobial activity against Bifidobacterium bifidum JCM 1255 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID278627Protein binding in monkey serum at 100 ug/ml2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534681Antimicrobial activity against Veillonella parvula ATCC 10790 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520436AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534445Antimicrobial activity against Bifidobacterium adolescentis ATCC 15703 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520931Drug level in human serum at 700 mg2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534679Antimicrobial activity against Desulfovibrio piger DSM 749 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520460Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 36 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278648Clearance in rat at 50 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID534466Antimicrobial activity against carbapenemase-producing Bacteroides fragilis GAI 30079 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID528913Drug metabolism in human with creatinine clearance of 50-79 ml/min assessed as RO4957463 apparent half life at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520677T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520950Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534434Antimicrobial activity against Gemella morbillorum ATCC 27824 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520453AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278645AUC (0-inf) in monkey at 25 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID520686T>MIC for 2-log drop in count in methicillin-sensitive Staphylococcus aureus 5956 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529028Renal clearance in human with creatinine clearance of 30-49 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID528896Volume of distribution at steady state in human with creatinine clearance of => 80 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID529037Dose normalized excretion in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545342Displacement of [14C]benzylpenicillin from PBP4 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520529Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520532Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 1500 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545573Antibacterial activity against Pseudomonas aeruginosa PMR2a selected at 2 times MIC of meropenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520695T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534678Antimicrobial activity against Desulfovibrio desulfuricans ATCC 29577 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520427AUBKC (0 to 24 hrs) in methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520452AUBKC (0 to 48 hrs) in methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520691T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529858Ratio of MIC for Pseudomonas aeruginosa N043 to MIC for Pseudomonas aeruginosa PAO12008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID520528Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as time required to 99.9% killing at 750 mg, iv every 8 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520469Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520159Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID278644AUC (0-inf) in monkey at 10 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID520048Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 in in vitro pharmacokinetic model assessed as viable count at 4 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID519938Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 by broth dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520939Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534471Antimicrobial activity against Bacteroides thetaiotaomicron ATCC 29741 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534461Antimicrobial activity against Bacteroides fragilis ATCC 25285 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534477Antimicrobial activity against Prevotella bivia ATCC 29303 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520142Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520041Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 in in vitro pharmacokinetic model assessed as viable count at 2 times of MIC2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545558Ratio of MIC for Escherichia coli EIR2a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545341Displacement of [14C]benzylpenicillin from PBP3 in Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520942Antibacterial activity against methicillin-resistant Staphylococcus aureus 33829 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 1500 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528889Apparent half-life in human with creatinine clearance of 50-79 ml/min at 1500 mg, iv administered as single dose2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID520653T>MIC for static effect in methicillin-resistant Staphylococcus aureus 33922 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID529848Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID519939Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 by broth dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID528904Drug metabolism in human with creatinine clearance of => 80 ml/min assessed as RO4957463 Cmax at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545348Displacement of [14C]benzylpenicillin from PBP3 in Pseudomonas aeruginosa ATCC 156922009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520675T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534468Antimicrobial activity against Bacteroides vulgatus GAI 0673 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545546Ratio of MIC for Staphylococcus aureus SMR2a to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520936Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as time required to 99% killing at 750 mg, iv every 8 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520466Antibacterial activity against methicillin-resistant Staphylococcus aureus 33922 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534430Antimicrobial activity against Parvimonas micra VPI 5464-1 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID545553Antibacterial activity against Escherichia coli ERR4a selected at 4 times MIC of tomopenem by microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID529033Drug excretion in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose after 24 hrs2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545544Ratio of MIC for Staphylococcus aureus SIR2a selected at 2 times MIC of imipenem to MIC for Staphylococcus aureus ATCC 6538P2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520681T>MIC for 4-log drop in count in methicillin-resistant Staphylococcus aureus 33815 in in vitro pharmacokinetic model after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520138Antibacterial activity against methicillin-resistant Staphylococcus aureus 33921 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 12 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID545560Ratio of MIC for Escherichia coli EIR2b to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545550Ratio of MIC for Escherichia coli ERR2a selected to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520161Antibacterial activity against methicillin-resistant Staphylococcus aureus 33827 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520692T>MIC for 3-log drop in count in methicillin-resistant Staphylococcus aureus 33827 in in vitro pharmacokinetic model after 24 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID528899Volume of distribution at steady state in human with creatinine clearance of =< 30 ml/min at 1500 mg, iv administered as single dose measured after 60 mins2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
AID545568Ratio of MIC for Escherichia coli EMR2a to MIC for Escherichia coli NIHJ2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520149Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520527Antibacterial activity against methicillin-resistant Staphylococcus aureus 33815 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 1500 mg, iv every 8 hrs measured after 48 hrs using 10'8 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID534457Antimicrobial activity against Lactobacillus plantarum JCM 1149 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID534444Antimicrobial activity against Actinomyces odontolyticus GAI 91002 by agar dilution method in presence of 5% laked sheep blood2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
AID520077Antibacterial activity against methicillin-sensitive Staphylococcus aureus 5956 infected in in vitro pharmacokinetic model assessed as reduction in viable count at 750 mg, iv every 8 hrs measured after 48 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
AID520641Antibacterial activity against methicillin-resistant Staphylococcus aureus 33820 assessed as viable count at 2 times of MIC after 24 hrs using 10'6 CFU/ml inoculum2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (84.21)29.6817
2010's3 (15.79)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.73 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (10.53%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (89.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		2.0410acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
aminocaproic acid
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.		2.0410amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		2.0410monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
enprofylline
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.		2.4520oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		2.4520acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol
Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.		2.4520aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		2.4520acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		2.4520monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
albuterol
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).		2.4520phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
alfuzosin
alfuzosin: structure given in first source		2.0410monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
alosetron
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.		2.0410imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
alprazolam
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.		2.4520organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
alprenolol
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.		2.4520secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		2.4520adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
diatrizoic acid
Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.		2.0410acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
theophylline
[no description available]		2.4520dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
amiodarone
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.		2.45201-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound		cardiovascular drug
dan 2163
[no description available]		2.0510aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone		environmental contaminant;
second generation antipsychotic;
xenobiotic
amitriptyline
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.		2.4520carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		2.4520dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		2.0410acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
antipyrine
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.		2.4520pyrazoloneantipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.4520benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		2.4520ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
azelastine
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.		2.4520monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
betaxolol
[no description available]		2.4520propanolamineantihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bevantolol
bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.		2.4520propanolamineanti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker
biperiden
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.		2.0410piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
bisoprolol
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.		2.4520secondary alcohol;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
bromazepam
Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.		2.4520organic molecular entity
bromopride
bromopride: RN given refers to parent cpd; structure		2.4520benzamides
brotizolam
brotizolam: structure		2.0410organic molecular entity
buflomedil
buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure		2.4520aromatic ketone
bumetanide
[no description available]		2.4520amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin
bunazosin: structure		2.0410quinazolines
bupivacaine
Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.		2.4520aromatic amide;
piperidinecarboxamide;
tertiary amino compound
busulfan
[no description available]		2.4520methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
caffeine
[no description available]		2.4520purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.4520aromatic ether;
nitrile;
polyether;
tertiary amino compound
metrizoate
Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.		2.4520monocarboxylic acidradioopaque medium
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.0410N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
carvedilol
[no description available]		2.4520carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		2.4520aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		2.4520benzodiazepine
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.4520aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chlorpheniramine
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.		2.4520monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		2.4520organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
chlorpropamide
Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.		2.4520monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorthalidone
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.		2.4520isoindoles;
monochlorobenzenes;
sulfonamide
cifenline
[no description available]		2.4520diarylmethane
cimetidine
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.		2.4520aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.4520aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
citalopram
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.		2.45202-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		2.0410dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
clonazepam
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.		2.45201,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		2.4520clonidine;
imidazoline
chlorazepate
clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.		2.04101,4-benzodiazepinoneanticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug
dapsone
[no description available]		2.4520substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		2.4520dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
nordazepam
Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.		2.04101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		2.0410primary amine
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.45201,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		2.4520benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		2.4520amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
diflunisal
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.		2.0410monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
diphenhydramine
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.		2.4520ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
disopyramide
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.		2.4520monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		2.4520branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		2.4520benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
doxapram
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.		2.0410morpholines;
pyrrolidin-2-ones		central nervous system stimulant
doxazosin
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.		2.0410aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
doxepin
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.		2.4520dibenzooxepine;
tertiary amino compound		antidepressant
dyphylline
Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.		2.0410oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
enoxacin
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.		2.04101,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		2.0410aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
etilefrine
Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.		2.4520phenols
felodipine
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.		2.4520dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
berotek
Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.		2.0410resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
fenspiride
fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma		2.0410azaspiro compound
fentanyl
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.		2.4520anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
flecainide
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).		2.4520aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines		anti-arrhythmia drug
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		2.4520difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.4520conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		2.4520aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
flumazenil
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.		2.4520ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
flunitrazepam
Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.		2.04101,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
fluorescite
fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.		2.0410benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye		fluorescent dye;
radioopaque medium
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.4520nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		2.4520carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		2.4520chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
gabapentin
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.		2.4520gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
glimepiride
glimepiride: structure given in first source		2.4520sulfonamide
glipizide
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.		2.4520aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		2.4520monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
granisetron
[no description available]		2.4520aromatic amide;
indazoles
guanfacine
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.		2.4520acetamides
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		2.4520aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
hexobarbital
Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.		2.4520barbiturates
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		2.4520azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
hydroflumethiazide
Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.		2.0410benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
hydroxychloroquine
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.		2.0410aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
hydroxyurea
[no description available]		2.4520one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
hypericin
[no description available]		2.0410
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		2.4520monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
lidocaine
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.		2.4520benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
ifosfamide
[no description available]		2.4520ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		2.4520dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.		2.4520bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.4520aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
iohexol
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.		2.0410benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
iopromide
iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.		2.4520dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
iothalamic acid
Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.		2.0410organic molecular entity
avapro
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.		2.0410azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.0410carbohydrazideantitubercular agent;
drug allergen
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		2.0410catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
isradipine
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.		2.4520benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
itraconazole
[no description available]		2.4520piperazines
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		2.0410cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		2.4520aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		2.4520benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
ketorolac
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.		2.4520amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate		analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
labetalol
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.		2.4520benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound
lansoprazole
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.		2.4520benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
letrozole
[no description available]		2.4520nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
lorazepam
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.		2.4520benzodiazepine
losartan
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position		2.4520biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
maprotiline
Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.		2.0410anthracenes
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		2.4520aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
meperidine
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.		2.4520ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound		antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
mepivacaine
Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.		2.0410piperidinecarboxamidedrug allergen;
local anaesthetic
meprobamate
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)		2.0410organic molecular entity
mesalamine
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.		2.0410amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols		non-steroidal anti-inflammatory drug
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		2.4520guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methadone
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.		2.4520benzenes;
diarylmethane;
ketone;
tertiary amino compound
methapyrilene
Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.		2.0410ethylenediamine derivativeanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
methylphenidate
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.		2.4520beta-amino acid ester;
methyl ester;
piperidines
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		2.4520benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
metolazone
Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.		2.4520organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		2.4520aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.7430C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
mexiletine
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.		2.4520aromatic ether;
primary amino compound		anti-arrhythmia drug
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		2.4520imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
milrinone
[no description available]		2.4520bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
mirtazapine
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.		2.4520benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.4520dihydroxyanthraquinoneanalgesic;
antineoplastic agent
moclobemide
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.		2.4520benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
acecainide
Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.		2.4520acetamides;
benzamides		anti-arrhythmia drug
naratriptan
naratriptan: structure given in first source		2.4520heteroarylpiperidine;
sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
nefazodone
nefazodone: may be useful as an opiate adjunct		2.4520aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nefopam
Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.		2.0410benzoxazocine;
tertiary amino compound
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.4520cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
nicardipine
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.		2.4520benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		2.4520C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nimodipine
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.		2.45202-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nisoldipine
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.		2.4520C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		2.45201,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
nitrendipine
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.		2.4520C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nizatidine
[no description available]		2.45201,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist
nomifensine
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.		2.4520isoquinolinesdopamine uptake inhibitor
nortriptyline
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.		2.4520organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2.45203-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		2.4520aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		2.0410carbazoles
oxazepam
Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.		2.45201,4-benzodiazepinone;
organochlorine compound		anxiolytic drug;
environmental contaminant;
xenobiotic
oxiracetam
oxiracetam: structure in first source		2.0410organonitrogen compound;
organooxygen compound
oxybutynin
oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.		2.0410acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
pamidronate
[no description available]		2.0410phosphonoacetic acid
pantoprazole
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.		2.4520aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		2.4520benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		2.0410aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
pentobarbital
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		2.0410barbituratesGABAA receptor agonist
pentoxifylline
[no description available]		2.0410oxopurine
perphenazine
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.		2.4520N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenacetin
Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione		2.0410acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		2.4520barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
moxonidine
moxonidine: structure given in first source		2.4520organohalogen compound;
pyrimidines
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		2.0410benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pindolol
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.		2.4520indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
piretanide
piretanide: potent inhibitor of chloride transport; structure		2.4520aromatic ether
practolol
Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.		2.0510acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		2.4520aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine
Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.		2.0410amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		2.0410aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		2.4520benzoic acids;
sulfonamide		uricosuric drug
procainamide
Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.		2.4520benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
prochlorperazine
Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.		2.0410N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
procyclidine
Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.		2.0410pyrrolidines;
tertiary alcohol		antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist
promazine
Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.		2.0410phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		2.4520phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
propafenone
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.		2.0410aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
propofol
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.		2.0410phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		2.4520naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
pyridostigmine
[no description available]		2.4520pyridinium ion
pyrimethamine
Maloprim: contains above 2 cpds		2.0410aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rabeprazole
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.		2.4520benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
ranitidine
[no description available]		2.4520aralkylamine
risperidone
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.		2.45201,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
rizatriptan
rizatriptan: structure given in first source; RN given refers to benzoate		2.4520tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
sulfadiazine
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.		2.4520pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
risedronic acid
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.		2.4520pyridines
sotalol
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.		2.4520ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
imatinib
[no description available]		2.4520aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.0410dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		2.4520isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfinpyrazone
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.		2.4520pyrazolidines;
sulfoxide		uricosuric drug
sulfisoxazole
Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.		2.4520isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
sulpiride
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.		2.0510benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
sumatriptan
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.		2.4520sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
suprofen
Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.		2.4520aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.4520naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		2.4520N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
temozolomide
[no description available]		2.0410imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
terazosin
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia		2.4520furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
terbutaline
Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.		2.4520phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		2.0410phthalimides;
piperidones
thiotepa
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).		2.4520aziridines
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		2.4520imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tizanidine
tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.		2.4520benzothiadiazole;
imidazoles		alpha-adrenergic agonist;
muscle relaxant
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		2.4520N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
ultram
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.		2.4520aromatic ether;
tertiary alcohol;
tertiary amino compound
tranexamic acid
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.		2.0410amino acid
trazodone
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.		2.0410monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
triamterene
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.		2.4520pteridinesdiuretic;
sodium channel blocker
triazolam
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.		2.4520triazolobenzodiazepinesedative
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.4520aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		2.4520
trimipramine
Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.		2.0410dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
urapidil
[no description available]		2.0410piperazines
venlafaxine
venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.		2.4520cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
viloxazine
Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.		2.0410aromatic ether
zaleplon
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.		2.4520nitrile;
pyrazolopyrimidine		anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative
zolpidem
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.		2.4520imidazopyridinecentral nervous system depressant;
GABA agonist;
sedative
zopiclone
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.		2.4520monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		2.452011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
cephaloridine
Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.		2.0410beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		2.452011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.4520penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.4520C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
vincristine
[no description available]		2.0410acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
ethinyl estradiol
Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.		2.041017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		2.0410aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
cephalothin
Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.		2.0410azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes		antibacterial drug;
antimicrobial agent
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.0410kanamycinsbacterial metabolite
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		2.4520amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		2.7330penicillin allergen;
penicillin		antibacterial drug
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.0410alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
oxacillin
Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.		2.7330penicillinantibacterial agent;
antibacterial drug
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.4520beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		2.041011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		2.4520benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
dichloroacetic acid
[no description available]		2.0410monocarboxylic acid;
organochlorine compound		astringent;
marine metabolite
methylprednisolone
Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.		2.45206-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
penicillin v
Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.		2.4520penicillin allergen;
penicillin
isosorbide dinitrate
Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.		2.0410glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
ergotamine
Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.		2.0410peptide ergot alkaloidalpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent
neostigmine bromide
neostigmine bromide : The bromide salt of neostigmine.		2.0410bromide salt
nafcillin
Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.		2.4520penicillin allergen;
penicillin		antibacterial drug
methohexital
Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.		2.0410acetylenic compound;
barbiturates		drug allergen;
intravenous anaesthetic
pirinitramide
Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.		2.4520nitrile
edrophonium bromide
[no description available]		2.0410
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		2.0410N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		2.4520benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
betamethasone
Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)		2.452011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
dextropropoxyphene
Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.		2.04101-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoatemu-opioid receptor agonist;
opioid analgesic
ketobemidone
ketobemidone: structure		2.0410piperidines
chlormethiazole
Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.		2.4520thiazoles
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		2.0410amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
lithium carbonate
Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.		2.0410carbonate salt;
lithium salt		antimanic drug
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0410acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.4520cyclic ketone;
erythromycin
levonorgestrel
Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.		2.041017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
lormetazepam
lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.		2.45201,4-benzodiazepinone;
organochlorine compound		sedative
vinblastine
[no description available]		2.4520
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.4520ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.7330glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
metylperon
metylperon: RN given refers to parent cpd		2.0410aromatic ketone
spectinomycin
Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.		2.0410cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound		antibacterial drug;
antimicrobial agent;
bacterial metabolite
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		2.0410benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
benperidol
Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)		2.0410aromatic ketone
chlordesmethyldiazepam
[no description available]		2.0410benzodiazepine
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.4520dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine
doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.		2.4520organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
dicloxacillin
Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.		2.4520dichlorobenzene;
penicillin		antibacterial drug
streptomycin
[no description available]		2.0410antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
cladribine
[no description available]		2.4520organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
carbenicillin
Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.		2.4520penicillin allergen;
penicillin		antibacterial drug
floxacillin
Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.		2.4520penicillin allergen;
penicillin		antibacterial drug
beclomethasone dipropionate
beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.		2.041011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester		anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug
olsalazine
olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.		2.0410azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
terodiline
[no description available]		2.4520diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene
1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd		2.0410
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.0410pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
metocurine iodide
[no description available]		2.4520aromatic ether
apazone
Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.		2.0410benzotriazinesnon-steroidal anti-inflammatory drug;
uricosuric drug
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		2.4520selegiline;
terminal acetylenic compound		geroprotector
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		2.4520beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
isosorbide-5-mononitrate
isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug		2.4520glucitol derivative;
nitrate ester		nitric oxide donor;
vasodilator agent
cephapirin
Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.		2.0410cephalosporinantibacterial drug
pregnanolone
Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.		2.04103-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
du-21220
Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.		2.0410benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound
ribostamycin
Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).		2.0410amino cyclitol glycoside;
aminoglycoside antibiotic		antibacterial drug;
antimicrobial agent;
metabolite
cefazolin
Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.		2.4520beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		2.4520penicillin allergen;
penicillin		antibacterial drug
timolol
(S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.		2.4520timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
indoramin
Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.		2.0410tryptamines
toloxatone
toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.		2.4520oxazolidinone;
primary alcohol;
toluenes
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.4520azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
sisomicin
Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).		2.4520amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
amdinocillin
Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.		2.0410penicillinantibacterial drug;
antiinfective agent
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		2.4520amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.4520taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		2.0410beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
ticarcillin
Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.		2.4520penicillin allergen;
penicillin		antibacterial drug
trimazosin
trimazosin: RN given refers to parent cpd; structure		2.0410N-arylpiperazine
ribavirin
Rebetron: Rebetron is tradename		2.45201-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam
adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.		2.4520triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative
amikacin
Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.		2.4420alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide		antibacterial drug;
antimicrobial agent;
nephrotoxin
tolamolol
[no description available]		2.0410
cephradine
Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.		2.4520beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
methyldopa
Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.		2.4520L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
tocainide
Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.		2.4520monocarboxylic acid amideanti-arrhythmia drug;
local anaesthetic;
sodium channel blocker
sulbenicillin
Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.		2.4520penicillin
sq-11725
Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.		2.4520
diltiazem
Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.		2.45205-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
vecuronium bromide
Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.		2.0410organic bromide salt;
quaternary ammonium salt		muscle relaxant;
neuromuscular agent;
nicotinic antagonist
meptazinol
Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.		2.4520azepanes
sufentanil
Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.		2.4520anilide;
ether;
piperidines;
thiophenes		anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
torsemide
Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.		2.4520aminopyridine;
N-sulfonylurea;
secondary amino compound		antihypertensive agent;
loop diuretic
medroxalol
medroxalol: RN given refers to parent cpd without isomeric designation		2.0410salicylamides
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		2.4520aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole
Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.		2.0410cephalosporinantibacterial drug
lorcainide
[no description available]		2.4520acetamides
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		2.4520anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
ceforanide
ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.		2.0410cephalosporinantibacterial drug
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		2.4520penicillin allergen;
penicillin		antibacterial drug
paroxetine
Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.		2.4520aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		2.4520alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone
Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.		2.0410cephalosporinantibacterial drug
atracurium
Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.		2.0410diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
moxalactam
Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.		2.4520cephalosporin;
oxacephem		antibacterial drug
endralazine
BQ 22-708: RN given refers to parent cpd		2.0410benzamides
cefadroxil anhydrous
Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.4520cephalosporinantibacterial drug
encainide
Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.		2.4520benzamides;
piperidines		anti-arrhythmia drug;
sodium channel blocker
pefloxacin
Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.		2.4520fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
alfentanil
Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.		2.4520monocarboxylic acid amide;
piperidines		central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug
cefotetan
Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.		2.0410
recainam
recainam: structure given in first source		2.4520
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		2.4520delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
flupirtine
flupirtine: RN given refers to parent cpd without isomeric designation		2.4520aminopyridine
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		2.4520aromatic ketone
idazoxan
Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.		2.0410benzodioxine;
imidazolines		alpha-adrenergic antagonist
remoxipride
Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.		2.4520dimethoxybenzene
pravastatin
Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		2.45203-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
bambuterol
bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.		2.0410carbamate ester;
phenylethanolamines		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent
atomoxetine
atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.		2.4520aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
trospectomycin
trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer		2.0410dioxanes
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		2.45203-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
sematilide
sematilide: RN refers to HCl; structure given in first source		2.4520
esmolol
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.		2.0410aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound
clinafloxacin
clinafloxacin: structure given in first source; RN given is for monoHCl		2.4520quinolines
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		2.45206-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
loxiglumide
loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source		2.0410organic molecular entity
sparfloxacin
[no description available]		2.4520fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		2.4520phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
tiagabine
Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.		2.4520beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes		anticonvulsant;
GABA reuptake inhibitor
mibefradil
Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.		2.0410tetralinsT-type calcium channel blocker
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.4520pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac
bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.		2.4520aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		2.4520organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
ibutilide
ibutilide: RN & structure in first source; RN refers to the fumarate salt		2.4520benzenes;
organic amino compound
aripiprazole
Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.		2.0410aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone		drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
remifentanil
Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.		2.4520alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester		intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative
lamivudine
[no description available]		2.4520monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
irinotecan
[no description available]		2.4520carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
valsartan
Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.		2.4520biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
ibandronic acid
Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.		2.0410
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		2.45201,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
zanamivir
Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.		2.4520guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan
zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.		2.4520oxazolidinone;
tryptamines		anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
tirofiban
Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.		2.4520L-tyrosine derivative;
piperidines;
sulfonamide		anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
cisatracurium
cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R*,2'R*)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.		2.0410diester;
quaternary ammonium ion		muscle relaxant;
nicotinic antagonist
fosinoprilat
fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.		2.0410L-proline derivative;
phosphinic acids		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin
trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.		2.4520
cefprozil
[no description available]		2.0410cephalosporin;
semisynthetic derivative		antibacterial drug
iopamidol
Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.		2.0410benzenedicarboxamide;
organoiodine compound;
pentol		environmental contaminant;
radioopaque medium;
xenobiotic
imipramine n-oxide
imipramine N-oxide: RN given refers to parent cpd; structure		2.0410dibenzooxazepine
dexloxiglumide
dexloxiglumide: a CCK receptor antagonist; structure given in first source		2.4520glutamic acid derivative
intoplicine
intoplicine: structure in first source		2.0410pyridoindole
repaglinide
[no description available]		2.4520piperidines
telmisartan
Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.		2.4520benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
dexfenfluramine
Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.		2.0410fenfluramineappetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
ethinyl estradiol-17-sulfate
ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer		2.0410
ethinylestradiol-3-sulfate
ethinylestradiol-3-sulfate: binds to albumin at 2 sites		2.041017beta-hydroxy steroid;
steroid sulfate		antineoplastic agent;
estrogen
cefcanel
cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure		2.0410
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		2.45201,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
epristeride
epristeride: structure given in first source		2.4520steroid acid
talinolol
[no description available]		2.4520ureas
denaverine
denaverine: RN given refers to parent cpd; structure		2.0410diarylmethane
diprafenone
diprafenone: structure given in first source		2.4520aromatic compound
nebivolol
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.		2.0410chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
uk 68798
[no description available]		2.4520aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		2.4520carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
dexrazoxane
Dexrazoxane: The (+)-enantiomorph of razoxane.		2.4520razoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		2.0410conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
betamipron
[no description available]		2.0410organonitrogen compound;
organooxygen compound
bufuralol
bufuralol: RN given refers to cpd without isomeric designation; structure		2.4520benzofurans
panipenem
panipenem: synthetic cpd; structure given in first source		2.4520organic molecular entity
perindoprilat
perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.		2.0410dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound		antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
7-hydroxystaurosporine
[no description available]		2.0410
methotrimeprazine
Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.		2.0410phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
9-aminocamptothecin
[no description available]		2.0410pyranoindolizinoquinoline
sch 34343
Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer		2.4520
squalamine
squalamine: from dogfish shark Squalus acanthias; structure given in first source		2.0410bile acid
doripenem
Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.		2.0510carbapenems
atovaquone
Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.		2.4520hydroxy-1,2-naphthoquinone
rivastigmine
[no description available]		2.4520carbamate ester;
tertiary amino compound		cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent
frovatriptan
[no description available]		2.4520carbazoles
eletriptan
eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.		2.0410indoles;
N-alkylpyrrolidine;
sulfone		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
rosiglitazone
[no description available]		2.4520aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.0410macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2.45203-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
mci 9038
[no description available]		2.0410peptide
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.7330beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
bosentan anhydrous
Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.		2.0410primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
asulacrine
asulacrine: derivative of amsacrine; structure given in first source		2.0410acridines
hydroxycotinine
hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).		2.0410N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
quinaprilat
quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.		2.4520dicarboxylic acid;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent
2-hydroxyimipramine
2-hydroxyimipramine: RN given refers to parent cpd		2.4520dibenzoazepine
ecteinascidin 743
[no description available]		2.0410acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
almotriptan
almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.		2.4520indoles;
sulfonamide;
tertiary amine		non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
mk 0663
[no description available]		2.0410bipyridines;
organochlorine compound;
sulfone		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
gefitinib
[no description available]		2.0410aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
methotrexate
[no description available]		2.4520dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
tamsulosin
[no description available]		2.45205-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
sulbactam
[no description available]		2.4520penicillanic acids
dilevalol
(R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.		2.04102-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
carbapenems
[no description available]		6.12162
docetaxel
[no description available]		2.4520hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
irofulven
irofulven: structure in first source		2.0410cyclohexenones
ym 872
YM 872: structure in first source		2.0410
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.96409-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
ertapenem
Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.		2.4520carbapenemcarboxylic acid;
pyrrolidinecarboxamide		antibacterial drug
dx 8951
[no description available]		2.0410pyranoindolizinoquinoline
cilomilast
[no description available]		2.4520methoxybenzenes
conivaptan
conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).		2.0410benzazepineaquaretic;
vasopressin receptor antagonist
tezosentan
tezosentan: structure in first source		2.0410
sabarubicin
sabarubicin: structure given in first source		2.0410
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.4520aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
clevidipine
clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source		2.0410dihydropyridine
solifenacin
[no description available]		2.4520isoquinolines
xamoterol
Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.		2.4520morpholines
abanoquil
[no description available]		2.0410
anidulafungin
Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.		2.0410antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		2.4520
ropivacaine
Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.		2.0410piperidinecarboxamide;
ropivacaine		local anaesthetic
melagatran
[no description available]		2.4520azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor
tesaglitazar
tesaglitazar: structure in first source		2.4520
bms204352
BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source		2.0410
fosfluconazole
fosfluconazole: prodrug of fluconazole		2.0410conazole antifungal drug;
triazole antifungal drug;
triazoles		prodrug
cp 101,606
traxoprodil mesylate: a selective NMDA antagonist; structure given in first source		2.4520
nsc-89199
estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.		2.0410carbamate ester;
organochlorine compound;
steroid phosphate
phenethicillin
phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.		2.0410penicillin allergen;
penicillin
acivicin
[no description available]		2.0410isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
bortezomib
[no description available]		2.0410amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		2.4520cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		3.5480alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		2.0410beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
digitoxin
Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.		2.0410cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		2.0410L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
pancuronium
Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.		2.0410acetate ester;
steroid ester		cholinergic antagonist;
muscle relaxant;
nicotinic antagonist
rocuronium
Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.		2.04103alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound		drug allergen;
muscle relaxant;
neuromuscular agent
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		2.45202,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
netilmicin
Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.		2.4520
miglitol
[no description available]		2.4520piperidines
linezolid
[no description available]		2.4520acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
tolterodine
[no description available]		2.4520tertiary amineantispasmodic drug;
muscarinic antagonist;
muscle relaxant
darifenacin
darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.		2.04101-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
fluticasone propionate
fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.		2.041011beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester		adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug
acarbose
[no description available]		2.0410amino cyclitol;
glycoside
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		2.4520macrolide lactambacterial metabolite;
immunosuppressive agent
cerivastatin
cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.		2.4520dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin
rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).		2.4520dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		2.4520benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		2.7430
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		2.4520epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.4520macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
bms 214662
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.		2.0410benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
eptifibatide
[no description available]		2.0410homodetic cyclic peptide;
macrocycle;
organic disulfide		anticoagulant;
platelet aggregation inhibitor
gs 4071
GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.		2.4520acetate ester;
amino acid;
cyclohexenecarboxylic acid;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
marine xenobiotic metabolite
decitabine
[no description available]		2.45202'-deoxyribonucleoside
sm 8668
Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive		2.0410
teniposide
[no description available]		2.4520aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine
troxacitabine: shows good anti-HIV activity without cytotoxicity		2.0410carbohydrate derivative;
nucleobase-containing molecular entity
cefamandole
Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.		2.4520cephalosporin;
semisynthetic derivative		antibacterial drug
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		2.04101,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		2.4520L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
sitafloxacin
[no description available]		2.4520fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		2.4520nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
dibekacin
Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.		2.0410kanamycinsantibacterial agent;
protein synthesis inhibitor
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		2.0410antibiotic antifungal drug;
echinocandin		antiinfective agent
mezlocillin
Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.		2.4520penicillin allergen;
penicillin		antibacterial drug
tropisetron
Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.		2.0410indolyl carboxylic acid
leuprolide
Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.0410oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
fludarabine
[no description available]		2.0410purine nucleoside
propylthiouracil
Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.		2.4520pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
etomidate
Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.		2.0410ethyl ester;
imidazoles		intravenous anaesthetic;
sedative
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		2.4520aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
cotinine
Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.		2.0410N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
methimazole
Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.		2.04101,3-dihydroimidazole-2-thionesantithyroid drug
drotaverin
drotaverin: Hungarian drug; RN given refers to parent cpd; structure		2.4520isoquinolines
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		2.4520cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
cancidas
[no description available]		2.0410
lincomycin
Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.		2.0410carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound		antimicrobial agent;
bacterial metabolite
thiopental
Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.		2.4520barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic
hmr 3647
[no description available]		2.4520
nelarabine
nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).		2.0410beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine
[no description available]		2.4520aromatic ether
dolasetron
[no description available]		2.0410indolyl carboxylic acid
or 1259
[no description available]		2.0410hydrazone;
nitrile;
pyridazinone		anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent
gestodene
Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer		2.0410steroidestrogen
quinine
[no description available]		2.4520cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
isepamicin
[no description available]		2.0410
ifetroban
ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative		2.0410benzenes;
monocarboxylic acid
lamifiban
lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass		2.0410N-acylglycine
telavancin
telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.		2.0410glycopeptideantibacterial drug;
antimicrobial agent
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		2.4520triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
tolcapone
Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.		2.45202-nitrophenols;
benzophenones;
catechols		antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin
[no description available]		2.04107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
clavulanic acid
Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.		2.4520oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort
Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.		2.452011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
eprosartan
eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.		2.4520dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
montelukast
montelukast: a leukotriene D4 receptor antagonist		2.4520aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
mivacurium
Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.		2.0410isoquinolines
entacapone
entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.		2.45202-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol
[no description available]		2.4520hydroxy seco-steroid;
seco-cholestane		antiparathyroid drug
sdz psc 833
valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215		2.0410homodetic cyclic peptide
indocyanine green
[no description available]		2.04101,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye
codeine
[no description available]		2.4520morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		2.4520homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
hydromorphone
Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.		2.0410morphinane alkaloid;
organic heteropentacyclic compound		mu-opioid receptor agonist;
opioid analgesic
nalmefene
nalmefene: RN given refers to 5-alpha isomer		2.4520morphinane alkaloid
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		2.4520morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		2.4520organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		2.0410dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		2.4520morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
cicaprost
cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer		2.0410monoterpenoid
dexmedetomidine
[no description available]		2.0410medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
iloprost
Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.		2.0410carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
nalbuphine
Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.		2.4520organic heteropentacyclic compoundmu-opioid receptor antagonist;
opioid analgesic
nateglinide
Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.		2.4520phenylalanine derivative
vinorelbine
[no description available]		2.4520acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
romidepsin
depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.		2.0410cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.		2.0410dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
naltrexone
Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.		2.0410cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
morphine-6-glucuronide
morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer		2.0410morphinane alkaloid
butorphanol
Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.		2.4520morphinane alkaloidantitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
cefodizime
cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.04101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone
methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer		2.0410phenanthrenes
cefixime
[no description available]		2.4520cephalosporinantibacterial drug;
drug allergen
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		2.4520dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		2.4520dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
enalaprilat anhydrous
Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.		2.4520dicarboxylic acid;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefuroxime
[no description available]		2.45203-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether		drug allergen
ceftriaxone
[no description available]		2.45201,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime
Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.4520cephalosporin;
oxime O-ether		antibacterial drug
hr 810
cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.		2.0410cephalosporin;
cyclopentapyridine
ceftazidime
[no description available]		2.7330cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefetamet
cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.		2.4520cephalosporin
famotidine
[no description available]		2.45201,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		2.45201,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
aztreonam
[no description available]		2.4520beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
ginkgolide b
[no description available]		2.0410
palonosetron
Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.		2.0410azabicycloalkane;
delta-lactam;
organic heterotricyclic compound		antiemetic;
serotonergic antagonist
cefatrizine
Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.		2.4520amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles		antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
eniporide
eniporide: inhibits NHE-1 isoform; structure in first source		2.0410
cilastatin
[no description available]		2.4520carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide		EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic
ixabepilone
[no description available]		2.04101,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
azlocillin
Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.		2.4520penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial drug
verlukast
verlukast: LTD4 receptor antagonist		2.0410
ceftizoxime
[no description available]		2.4520cephalosporinantibacterial drug
carumonam
carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.		2.0410monobactamantibacterial drug
nitrofurantoin
Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.		2.4520imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
eritoran
eritoran : A lipid A derivative used for the treatment of severe sepsis.		2.0410lipid As
dantrolene
[no description available]		2.0410
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		2.0410artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
dexniguldipine
niguldipine: structure given in first source; clinical modulator of multidrug resistance		2.0410diarylmethane
napsagatran
napsagatran: structure given in first source		2.0410
temsirolimus
[no description available]		2.0410macrolide lactam
bms188797
[no description available]		2.0410
azimilide
azimilide: structure given in first source; RN given refers to dihydrochloride		2.0410imidazolidine-2,4-dione
bb-83698
BB-83698: peptide deformylase inhibitor		2.0410
zotarolimus
zotarolimus: synthetic analog of rapamycin; structure in first source		2.0410lactam;
macrolide
gentamicin sulfate
[no description available]		2.4520
bn 52020
[no description available]		2.0410
vindesine
[no description available]		2.0410
scopolamine hydrobromide
[no description available]		2.0410
bisaramil
[no description available]		2.0410
teicoplanin
teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.		2.4520
ly-146032
[no description available]		2.4520heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
dalbavancin
[no description available]		2.0410carbohydrate acid derivative;
glycopeptide;
monosaccharide derivative;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
cetrorelix
cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.		2.0410oligopeptideantineoplastic agent;
GnRH antagonist
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.4520
chlortetracycline
Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.		2.0410
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		2.4520
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		2.0410
roquinimex
roquinimex: structure in first source		2.0410aromatic amide
mobic
Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.		2.45201,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex
tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.		2.4520heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
isoxicam
isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.		2.4520benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.4520benzenes;
hydroxycoumarin;
methyl ketone
demeclocycline
Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.		2.0410
rolitetracycline
Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.		2.0410
tigecycline
[no description available]		2.4520
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.45202-aminopurines;
oxopurine		antimetabolite;
antiviral drug
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.4520cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		2.4520benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.0410dacarbazine
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.4520purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
ganciclovir
[no description available]		2.45202-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
sildenafil
sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.		2.4520piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		2.45202-aminopurines;
propane-1,3-diols		antiviral drug
vardenafil
vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.		2.4520imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		2.4520nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
leucovorin
5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.		2.4520formyltetrahydrofolic acidEscherichia coli metabolite;
mouse metabolite
tegaserod
tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source		2.4520carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		2.0410aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
aprepitant
Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.		2.0410(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
ceftobiprole
ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).		2.0410cephalosporin;
thiadiazoles		antimicrobial agent
rifabutin
[no description available]		2.4520
ConditionIndicatedRelationship StrengthStudiesTrials
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		03.4311
Bacterial Disease
[description not available]		03.8221
Bacterial Infections
Infections by bacteria, general or unspecified.		03.8221
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		03.4311
Infections, Pseudomonas
[description not available]		02.7430
Infections, Respiratory
[description not available]		02.0410
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.7430
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		02.0410
Infections, Staphylococcal
[description not available]		02.4620
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.4620
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0210
Bacterial Infections, Gram-Negative
[description not available]		02.0210
Bacterial Infections, Gram-Positive
[description not available]		02.0210
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		02.0210
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		02.0210
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0310